Immunomodulatory treatments in epilepsy

Area of Science:

• Neurology
• Immunology
• Pathophysiology

Background:

• Immunity and inflammation are increasingly recognized as integral to the pathogenesis of certain seizure disorders.
• Refractory epilepsy, in particular, may involve immune-mediated processes.
• Prompt intervention with immunotherapy can potentially lead to improved patient outcomes.

Purpose of the Study:

• To review the role of immune system dysregulation in epilepsy.
• To discuss current and emerging immunotherapy options for epilepsy management.
• To highlight the need for further research, including randomized controlled trials, in autoimmune epilepsy.

Main Methods:

• Literature review of studies on immunotherapy in epilepsy.
• Analysis of current treatment modalities including corticosteroids, immunoglobulins, plasmapheresis, and steroid-sparing agents.
• Examination of novel immunotherapies such as rituximab, efalizumab, and natalizumab.

Main Results:

• Established immunotherapies like corticosteroids and immunoglobulins are used for immune-mediated epilepsy.
• More aggressive treatments, including B-cell depleting agents and monoclonal antibodies, are being explored.
• Evidence suggests a significant role for immune pathways in specific epilepsy types.

Conclusions:

• Immunotherapy is a viable treatment strategy for presumed autoimmune epilepsy.
• Further randomized controlled trials are essential to validate the efficacy of immunotherapy in immune-mediated epilepsy.
• Timely immunotherapy may offer better prognoses for individuals with immune-related seizure disorders.